Cargando…
Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF
INTRODUCTION: Hypercoagulability in malignancy increases the risk of thrombosis, but is also involved in cancer progression. Experimental studies suggest that tissue factor (TF) and tissue factor pathway inhibitor (TFPI) are involved in cancer biology as a tumor- promoter and suppressor, respectivel...
Autores principales: | Tinholt, Mari, Vollan, Hans Kristian Moen, Sahlberg, Kristine Kleivi, Jernström, Sandra, Kaveh, Fatemeh, Lingjærde, Ole Christian, Kåresen, Rolf, Sauer, Torill, Kristensen, Vessela, Børresen-Dale, Anne-Lise, Sandset, Per Morten, Iversen, Nina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423106/ https://www.ncbi.nlm.nih.gov/pubmed/25882602 http://dx.doi.org/10.1186/s13058-015-0548-5 |
Ejemplares similares
-
Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study
por: Tinholt, Mari, et al.
Publicado: (2014) -
Coagulation factor V is a marker of tumor-infiltrating immune cells in breast cancer
por: Tinholt, Mari, et al.
Publicado: (2020) -
TFPIα and TFPIβ are expressed at the surface of breast cancer cells and inhibit TF-FVIIa activity
por: Stavik, Benedicte, et al.
Publicado: (2013) -
Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer
por: Aure, Miriam Ragle, et al.
Publicado: (2015) -
Indirect regulation of TFPI-2 expression by miR-494 in breast cancer cells
por: Andresen, Marianne S., et al.
Publicado: (2020)